Demir, L. And CANAZ, F. 2023. Nivolumab rechallenge after severe immune hepatitis in a metastatic renal cell cancer patient with hepatitis B and no detectable primary. Indian Journal of Cancer , vol.60, no.1 , 114-120.

Demir, L., & CANAZ, F., (2023). Nivolumab rechallenge after severe immune hepatitis in a metastatic renal cell cancer patient with hepatitis B and no detectable primary. Indian Journal of Cancer , vol.60, no.1, 114-120.

Demir, Lutfiye, And FUNDA CANAZ. "Nivolumab rechallenge after severe immune hepatitis in a metastatic renal cell cancer patient with hepatitis B and no detectable primary," Indian Journal of Cancer , vol.60, no.1, 114-120, 2023

Demir, Lutfiye And CANAZ, FUNDA. "Nivolumab rechallenge after severe immune hepatitis in a metastatic renal cell cancer patient with hepatitis B and no detectable primary." Indian Journal of Cancer , vol.60, no.1, pp.114-120, 2023

Demir, L. And CANAZ, F. (2023) . "Nivolumab rechallenge after severe immune hepatitis in a metastatic renal cell cancer patient with hepatitis B and no detectable primary." Indian Journal of Cancer , vol.60, no.1, pp.114-120.

@article{article, author={Lutfiye Demir And author={FUNDA CANAZ}, title={Nivolumab rechallenge after severe immune hepatitis in a metastatic renal cell cancer patient with hepatitis B and no detectable primary}, journal={Indian Journal of Cancer}, year=2023, pages={114-120} }